Editorial
doi: 10.1900/RDS.2005.2.116.
Epub 2005 Nov 10.
Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials
- PMID: 17491686
- PMCID: PMC1783560
- DOI: 10.1900/RDS.2005.2.116
Item in Clipboard
Editorial
Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials
Rev Diabet Stud.
2005 Fall.
No abstract available
Comment in
-
Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach.Rev Diabet Stud. 2005 Winter;2(4):187-9; discussion 190-1. doi: 10.1900/RDS.2005.2.187. Epub 2006 Feb 10. Rev Diabet Stud. 2005. PMID: 17491693 Free PMC article. No abstract available.
Similar articles
-
Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes.Expert Opin Investig Drugs. 2021 Dec;30(12):1209-1219. doi: 10.1080/13543784.2022.2022119. Epub 2022 Jan 10. Expert Opin Investig Drugs. 2021. PMID: 34936848 Review.
-
Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.Diabetes. 2007 Aug;56(8):2103-9. doi: 10.2337/db06-1632. Epub 2007 Apr 24. Diabetes. 2007. PMID: 17456848
-
Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain.J Autoimmun. 2017 Jan;76:115-122. doi: 10.1016/j.jaut.2016.10.001. Epub 2016 Oct 10. J Autoimmun. 2017. PMID: 27745778 Free PMC article.
-
The Hsp60 peptide p277 enhances anti-CD3 mediated diabetes remission in non-obese diabetic mice.J Autoimmun. 2015 May;59:61-6. doi: 10.1016/j.jaut.2015.02.003. Epub 2015 Mar 13. J Autoimmun. 2015. PMID: 25772283
-
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.Diabetes. 2013 Jan;62(1):9-17. doi: 10.2337/db12-0562. Diabetes. 2013. PMID: 23258904 Free PMC article. Review. No abstract available.
Cited by
-
"Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?Rev Diabet Stud. 2006 Winter;3(4):156-60. doi: 10.1900/RDS.2006.3.156. Epub 2007 Feb 10. Rev Diabet Stud. 2006. PMID: 17487339 Free PMC article. No abstract available.
-
Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach.Rev Diabet Stud. 2005 Winter;2(4):187-9; discussion 190-1. doi: 10.1900/RDS.2005.2.187. Epub 2006 Feb 10. Rev Diabet Stud. 2005. PMID: 17491693 Free PMC article. No abstract available.
References
-
- Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986;2:119–124. - PubMed
-
- Stiller CR, Dupre J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, Von Graffenried B, Wolfe BM. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science. 1984;223:1362–1367. - PubMed
-
- The Canadian-European Randomized Control Trial Group. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes. 1988;37:1574–1582. - PubMed
-
- Assan R, Timsit J, Feutren G, Bougneres P, Czernichow P, Hannedouche T, Boitard C, Noel LH, Mihatsch MJ, Bach JF. The kidney in cyclosporin A-treated diabetic patients: a long-term clinicopathological study. Clin Nephrol. 1994;41:41–49. - PubMed
-
- Assan R, Blanchet F, Feutren G, Timsit J, Larger E, Boitard C, Amiel C, Bach JF. Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients. Diabetes Metab Res Rev. 2002;18:464–472. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources